Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...

People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...

Some with severe sickle cell disease in England will now be able to access landmark CRISPR gene editing therapy, according to new health guidelines which were hailed as marking a “significant ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...